Stock VRCA VERRICA PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Verrica Pharmaceuticals Inc.

Equities

VRCA

US92511W1080

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
8.51 USD +2.16% Intraday chart for Verrica Pharmaceuticals Inc. -0.58% +16.26%
May. 15 Verrica Pharmaceuticals Amends Licensing Agreement With Torii Pharmaceutical for Phase 3 Trial of Ycanth MT
May. 15 Verrica Pharmaceuticals Inc. Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study Ycanth for the Treatment of Common Warts CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
GL
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
AQ
Lytix Biopharma Q1 2024 results - Promising clinical progress with important upcoming milestones
AQ
Verrica Pharmaceuticals : Company Presentation
PU
Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
GL
Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
AQ
Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results
GL
Verrica Pharmaceuticals to Present at Upcoming Investor Conferences
GL
Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024
GL
Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
GL
Verrica Pharmaceuticals Announces that YCANTH Receives New Chemical Entity Status and Orange Book Listing from the FDA
AQ
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
GL
VERRICA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
BU
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
GL
Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference
GL
Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024
GL
Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024
AQ
VERRICA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
BU
Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition
GL
Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VRCA Stock
  4. News Verrica Pharmaceuticals Inc.
  5. Press Releases